On June 10, Sino Biopharmaceutical fell 3.08% in regular trading, trading at 4.41 HKD/share, with trading volume of approximately 96.55 million HKD.

On the news front, Morgan Stanley recently published a research note cutting its target price for Sino Biopharmaceutical from 8.3 HKD to 7.8 HKD while maintaining an overweight rating. The bank incorporated the newly in-licensed bepirovirsen, expected to contribute revenue from 2027, and removed Sinovac LS dividend income assumptions per management guidance, reducing EPS forecasts for 2026 through 2028 by 8%, 7%, and 7% respectively. Additionally, the company announced on June 4 the cancellation of 40.35 million repurchased shares at an average price of 5.471 HKD, totaling approximately 221 million HKD, reducing total issued shares to about 18.705 billion.

The broader pharmaceutical sector remained under pressure, with Hengrui Pharma down 2.17%, Hutchmed down 0.77%, Hansoh Pharma down 0.63%, and Luye Pharma down 0.53%, reflecting continued systematic selling across the industry.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)